I

iRhythm Technologies

Wearable cardiac monitoring with data analysis

Vice President - M&A Integrations

Full-Time
$254k - $330k
Expert
Bachelor's, Master's, MBA
Solana Beach, CA, USA+1 moreMore locations: United States
HybridPeriodic travel is required based on transaction activity and business needs.
Project & Program ManagementProgram Management

About the job

Requirements
  • A bachelor's degree in Business, Finance, Economics, Engineering, Life Sciences, Healthcare Administration, or a related field is required.
  • At least 10 years of progressive experience across post-merger integration, enterprise transformation, strategic program leadership, operations, corporate development integration, or management consulting, including at least 5 years with direct M&A integration leadership accountability.
  • Proven experience leading multiple acquisitions through diligence, Day 1, stabilization, functional integration, and value realization.
  • Demonstrated experience building, managing, and developing teams that have directly integrated acquired companies, not solely advised or monitored integration activity.
  • Demonstrated success delivering measurable operational, commercial, organizational, and financial outcomes from complex transactions.
  • Experience leading cross-functional teams in highly matrixed, regulated organizations and influencing senior leaders without direct authority.
  • Strong cross-functional and organizational acumen, including experience with integration business cases, synergy models, one-time costs, budgets, and value realization plans.
  • Executive-level communication, facilitation, and presentation skills, with the judgment and presence to lead governance forums and advise senior executives.
  • Ability to connect strategy, people, process, technology, and economics into a coherent execution plan.
  • Hands-on leadership style with the ability to move fluidly between executive-level decisions and detailed operating issues.
  • Strong analytical, diagnostic, prioritization, and problem-solving skills.
  • Inclusive people leadership that develops talent, creates accountability, and builds effective teams across organizational boundaries.
  • Patient- and customer-centered decision making that balances speed and value capture with quality, regulatory, compliance, and business continuity requirements.
  • Working knowledge of quality, regulatory, and compliance considerations relevant to medical technology and healthcare businesses.
Responsibilities
  • Partner with Corporate Development and functional leaders during diligence to assess integration complexity, organizational impacts, operating model implications, risks, dependencies, and value creation opportunities.
  • Translate the transaction thesis into an actionable integration plan, inclusive of clear priorities, decision rights, milestones, and measurable outcome metrics.
  • Develop Day 1 readiness plans, stabilization priorities, and longer-term integration roadmaps tailored to the strategic rationale and risk profile of each transaction.
  • Identify critical business continuity requirements and establish mitigation and contingency plans before close.
  • Drive cross-functional plans for operating model alignment, organizational design, process integration, systems and data migration, customer and partner continuity, talent onboarding, and culture integration.
  • Own integrated milestone, dependency, risk, issue, and decision tracking; remove barriers and ensure commitments are delivered on time and within approved investment parameters.
  • Lead transaction close, Day 1, and major integration checkpoints, confirming readiness and escalating unresolved risks to the appropriate executive governance body.
  • Partner with Finance and business leaders to validate synergies, dis-synergies, one-time costs, investment requirements, and value creation initiatives.
  • Establish clear owners, baselines, targets, and measurement methods for strategic, operational, commercial, and financial outcomes.
  • Monitor and report integration health, milestone performance, synergy capture, and business impact through executive dashboards and recurring governance reviews.
  • Identify corrective actions and opportunities to accelerate value capture while balancing patient, customer, employee, quality, and regulatory considerations.
  • Lead change management and stakeholder engagement strategies that support adoption, minimize disruption, and strengthen the employee experience.
  • Partner with HR and business leaders on leadership alignment, organizational design, workforce transitions, retention of critical talent, and cultural integration.
  • Build trust and shared accountability across legacy iRhythm teams and acquired company leadership and employees.
  • Communicate integration priorities, decisions, progress, and implications clearly to audiences ranging from frontline teams to the Board.
  • Serve as a trusted advisor to the EVP, Strategy & Corporate Development and executive leadership on integration strategy, execution risk, tradeoffs, and value realization.
  • Lead, develop, and deploy an experienced integration team with direct accountability for integrating acquired companies, including dedicated integration leaders, program managers, and workstream resources as the portfolio requires.
  • Provide direction and coaching to functional integration leads, ensuring the teams doing the work have the capacity, tools, decision support, and accountability needed to deliver.
  • Develop and continuously improve iRhythm’s integration playbook, governance standards, diligence-to-integration handoffs, tools, templates, training, and lessons-learned processes.
  • Build a scalable enterprise integration capability that can support increased transaction volume and complexity over time.
Desired Qualifications
  • An MBA, MHA, or other relevant advanced degree.
  • Program management, change management, Lean, Six Sigma, or related certification.
  • Industry experience in healthcare services, medical device, diagnostics, life science tools, digital health, or another highly regulated healthcare environment.
  • Experience integrating businesses with complex combinations of products, technology, data, clinical evidence, quality systems, regulated operations, supply chains, and commercial channels.
  • Background in an active M&A environment, either in an internal corporate integration role or in management consulting with substantial hands-on integration execution responsibility.

About the company

iRhythm Technologies develops cardiac monitoring technology centered on the Zio Patch, a wearable device that records heart rhythms for up to 14 days. The patch is worn by patients to collect continuous heart data, which iRhythm analyzes and interprets to provide diagnostic insights to clinicians without frequent in-person visits. Compared with rivals, the Zio Patch focuses on long-duration, non-intrusive monitoring combined with integrated data analysis that supports telehealth and clinician workflows. Its goal is to improve arrhythmia detection and diagnostic accuracy while streamlining patient care through scalable wearable monitoring and data interpretation.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2006

Get referred to iRhythm Technologies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $224.2 million, up 20.1%, with 19.3% EBITDA margin.
  • Management raised 2026 revenue guidance to $880 million-$890 million on August 6, 2026.
  • VitalConnect's $65 million run-rate expands iRhythm into MCT and inpatient channels.

What critics are saying

  • June 8, 2026 breach exposed PHI; class actions filed in Northern California.
  • FDA warning letter on Zio AT remains open, delaying full regulatory normalization.
  • Baxter settlement cost $50 million; VitalConnect integration risk starts before 2027 synergies.

What makes iRhythm Technologies unique

  • Zio integrates wearables, AI review, and cloud workflows across ambulatory cardiac monitoring.
  • August 6, 2026 VitalConnect adds 30-day MCT and hospital-to-home monitoring.
  • iRhythm serves 8 million patients, giving unmatched installed trust and clinical data scale.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Holidays
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Employee Stock Purchase Plan
  • Mental Health Support
  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
ISS Source
Oct 9th, 2026
After ransomware attack, medical device maker alerting victims.

After ransomware attack, medical device maker alerting victims. Oct 9, 2026 | News By Gregory Hale San Francisco, California-based medical device maker, iRhythm Holdings, Inc., suffered a ransomware attack in June and is now informing victims of the attack. "On June 8, 2026, iRhythm Holdings, Inc. identified unauthorized activity involving data maintained on certain third-party-hosted business applications," the company said in a June filing with the Securities and Exchange Commission (SEC). "The company promptly activated its cybersecurity response plan and launched an investigation with the support of external advisors and cybersecurity experts to assess and contain the threat. "On June 9, 2026, the company received communications from a threat actor claiming to have obtained sensitive information, including proprietary data, patient protected health information and other personal information. The communications from the threat actor demanded payment in exchange for not publicly disclosing this information. "Since receipt of the communications, the company has confirmed that certain data was exfiltrated from those applications. On June 10, 2026, the company determined that the incident is material in light of the volume of the potentially affected data," the SEC notice said. The company said 298,647 people in Texas had information stolen alongside another 69,526 in South Carolina. iRhythm also filed breach notices in California. Attackers gained access. After the company completed its forensic investigation, it found attackers were on the site from June 3 through June 8. The hackers gained access to unidentified third-party-hosted business applications through a social engineering attack. On October 2 iRhythm provided an update regarding the incident. Following completion of the forensic investigation and subsequent review to determine the nature of the impacted data, the company just started notifying impacted individuals. Following the forensic investigation, iRhythm carried out a review to determine the nature of the impacted data. This review concluded the impacted data includes: Patient name; patient contact information, including address, email address, and phone number; iRhythm patient account number; iRhythm device serial number; patient insurance number; date of service; and date of birth. iRhythm said it has no evidence any personal information has been or will end up used to commit identity theft. However, beginning October 2, 2026, iRhythm began notifying impacted individuals for whom it maintains contact information. Notified individuals have been provided with instructions on best practices to protect their information. The company said out of an abundance of caution, those served by iRhythm should take steps to protect themselves. This includes protecting themselves against medical identity theft and identity fraud, placing a fraud alert/security freeze on their credit files, obtaining free credit reports, and remaining vigilant in reviewing financial account statements and credit reports for fraudulent or irregular activity on a regular basis. No impact to manufacturing. As iRhythm previously reported to the SEC, the company has not identified any impact to its products, clinical or medical device systems, connections to customers, manufacturing and distribution operations, patient safety, or ability to meet patient needs. The company still believes the incident will not have a material impact on its financial condition or results of operations. It said cybersecurity insurance that may cover certain losses associated with the incident. Although, it added, there can be no assurance that such coverage will be sufficient to cover all losses the company may incur. iRhythm manufactures its line of prescription-only ECG patch monitors and cardiac systems. iRhythm designs, develops, and commercializes wearable biosensors (such as the Zio monitor, Zio XT, and Zio AT) alongside cloud-based data analytics and its proprietary AI-driven Zio ECG Utilization Software (ZEUS). No further information was immediately available on who was behind the attack.

The Record
Oct 9th, 2026
iRhythm data breach exposes information of 360,000 patients after social engineering attack

Medical device maker iRhythm disclosed a data breach affecting at least 360,000 people following a June cyberattack. The incident occurred on 8 June when hackers accessed third-party systems through social engineering, the company said in regulatory filings this week. The stolen information includes names, addresses, phone numbers, patient account numbers, device serial numbers, insurance numbers, dates of service, and birth dates. Hackers had access to company systems between 3 June and 8 June. iRhythm, known for its Zio Patch cardiac monitoring sensor, said the breach did not affect clinical systems, medical devices, or operations. The company reported receiving ransom demands but provided no evidence of identity theft. iRhythm reported $224.2 million in Q2 revenue.

Yahoo Finance
Aug 15th, 2026
iRhythm beats Q2 revenue by 2.3%, adjusted EBITDA surges 65.7% to $43.3M

iRhythm reported strong second-quarter results, beating analyst estimates with revenue of $224.2 million, up 20.1% year-on-year. The cardiac monitoring company posted adjusted earnings per share of $0.58, significantly exceeding the $0.04 estimate. Adjusted EBITDA reached $43.3 million, a 65.7% beat against expectations. Management attributed the performance to sustained demand for the Zio platform and effective commercial execution across multiple healthcare channels. During the earnings call, analysts questioned management about synergies from the VitalConnect acquisition and the sustainability of margin gains. CEO Quentin Blackford emphasised the need for a multi-product approach in the cardiac monitoring market. The company raised its full-year revenue guidance to $885 million from $880 million. Operating margin improved to -1.1% from -10% in the prior-year quarter.

Yahoo Finance
Aug 12th, 2026
iRhythm shares fall 1.9% despite strong Q2 earnings after Truist slashes price target from $160 to $18

iRhythm Technologies shares fell 1.9% to $125.41 after Truist Securities slashed its price target from $160 to $18, despite maintaining a Buy rating. The dramatic cut overshadowed the company's strong second-quarter results, which saw revenue of $224.2 million, up 20.1% year-over-year, and earnings per share of $0.58, significantly beating consensus estimates. Following the earnings beat, iRhythm raised its full-year revenue guidance to $885 million at the midpoint. The cardiac monitoring company has experienced volatile trading, with 19 moves greater than 5% over the past year. iRhythm is down 28.4% year-to-date and trading 33.7% below its 52-week high of $189.25.

Yahoo Finance
Aug 10th, 2026
iRhythm beats Q2 estimates with $224M revenue and 19.3% EBITDA margin as cardiac monitoring platform gains traction

iRhythm Technologies reported second-quarter revenue of $224.2 million, up 20.1% year-on-year and beating analyst estimates of $219.2 million. The medical technology company's non-GAAP profit of $0.58 per share significantly exceeded consensus forecasts. The company attributed the performance to sustained demand for its Zio ambulatory cardiac monitoring platform and effective commercial execution across cardiology, primary care, and new healthcare channels. Operating margin improved to -1.1% from -10% in the prior-year quarter, driven by manufacturing automation and workflow optimisation. iRhythm raised its full-year revenue guidance to $885 million from $880 million. The company plans to leverage its pending VitalConnect acquisition to expand into mobile cardiac telemetry and remote patient monitoring markets.